AbbVie beats Q1 2026 earnings, raises full-year forecast
Summary
Skyrizi and Rinvoq together generated more than $6.6 billion in quarterly sales, far outpacing Humira's $688 million
Description
Skyrizi and Rinvoq together generated more than $6.6 billion in quarterly sales, far outpacing Humira's $688 million
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source